84 results
424B3
ATXI
Avenue Therapeutics Inc
10 May 24
Prospectus supplement
4:53pm
payments made to such holder, unless such holder enters into an agreement with the U.S. Department of Treasury to collect and provide substantial
424B5
ATXI
Avenue Therapeutics Inc
10 May 24
Prospectus supplement for primary offering
4:52pm
Stockholders’ Equity Letter”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), notifying us that we
8-K
ATXI
Avenue Therapeutics Inc
15 Mar 24
Other Events
7:15am
the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (the “Nasdaq”) notifying the Company that it was not in compliance
424B3
2wkzoylit390vj
2 Feb 24
Prospectus supplement
12:00am
8-K
f1v7f sr6wxrr
24 Nov 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
1:19pm
8-K
EX-99.1
290625altq t879bk
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-10.2
l07cx01wn8vx
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-99.2
8m2jr6fdzu ew
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
424B4
ukvck18xi77oy
2 Nov 23
Prospectus supplement with pricing info
9:00am
8-K
h0bli
28 Sep 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:25pm
8-K
6so7pxgyf6kussc
21 Jul 23
Other Events
4:37pm